Alzamend Neuro, Inc. (ALZN)
2025-07-31 | ||||
|---|---|---|---|---|
| Research and development | 1,740,867 | |||
| General and administrative | 959,334 | |||
| Total operating expenses | 2,700,201 | |||
| Loss from operations | -2,700,201 | |||
| Interest expense | 2,483 | |||
| Total other expense, net | -2,483 | |||
| Net loss | -2,702,684 | |||
| Basic net loss per common share | -1.28 | |||
| Basic weighted average common shares outstanding | 2,106,036 | |||
| Diluted net loss per common share | -1.28 | |||
| Diluted weighted average common shares outstanding | 2,106,036 | |||